Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glycopyrronium bromide to reduce salivary gland PSMA uptake
NL-OMON46014Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glycopyrronium in xerostomia, sponsored by Netherlands Cancer Institute. Started May 2018; status: active, not recruiting.
02
Drugs
glycopyrronium
03
Conditions
xerostomia
Beyond the preview
Go deeper on NL-OMON46014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46014.